StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultNov 16, 2026, 04:37 PM

Kyntra Bio Q3 Net Income $0.2M vs Loss; Cuts $60M Debt Obligation

AI Summary

Kyntra Bio announced its third quarter 2026 financial results, reporting revenue of $1.8 million and a net income from continuing operations of $0.2 million ($0.04 per share), a significant improvement from the prior year's net loss. The company also provided a business update, highlighting the restructuring of a royalty financing agreement which reduced its payment obligations by $60 million. Kyntra Bio decided to discontinue development of FG-3246 and FG-3180, anticipating substantial operating expense savings. The company ended the quarter with $44.1 million in cash and cash equivalents, projecting a runway into 2028, and plans to initiate a pivotal Phase 3 trial for roxadustat in early 2027, contingent on securing a strategic partnership or capital raise.

Key Highlights

  • Kyntra Bio reported Q3 2026 revenue of $1.8 million, up from $1.1 million in Q3 2025.
  • Q3 2026 net income from continuing operations was $0.2 million ($0.04/share), compared to a net loss of $13.1 million in Q3 2025.
  • Restructured royalty financing agreement, reducing maximum payment obligation by $60 million to $65 million.
  • Discontinued development of FG-3246 and FG-3180, expecting over $20 million in operating expense savings in 2027-2028.
  • Cash, cash equivalents, investments, and accounts receivable totaled $44.1 million as of September 30, 2026, with runway into 2028.
  • Initiation of pivotal Phase 3 trial for roxadustat planned for 1Q 2027, subject to partnership or capital raise.